EXOZYMES INC. has reported a significant stock option transaction involving Christopher Marlett, a director and ten percent owner of the company. This filing, dated October 19, 2026, highlights Marlett's acquisition of 10,000 shares through a stock option, which he can exercise at a price of $6.28 per share. This activity may reflect Marlett's confidence in the company's future performance.
EXOZYMES INC. operates in the biological products sector, specifically classified under SIC code 2836, which encompasses companies involved in the production of biological products without diagnostic substances. The company trades on the Nasdaq under the ticker symbol EXOZ and is categorized as an emerging growth company.
According to the filing, Marlett now holds a total of 3,808,476 shares following this transaction. The stock option is set to vest in twelve quarterly installments starting December 31, 2026, and will expire on October 1, 2033. The filing also notes that the shares are held by MDB Capital Holdings, LLC, over which Marlett has voting and dispositive authority.
This transaction may have implications for other stakeholders in the company, particularly investors and analysts monitoring EXOZYMES' activities in the competitive biological products market. The filing does not specify any immediate next steps following this transaction.
Details were not available in the SEC filing regarding any upcoming votes or additional filings related to this transaction.